Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma-Reference-Cited by-同舟云学术

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Published:2024-08-12 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Chakraborty Rajshekhar^ORCID,Cheruvalath Heloise,Patwari Anannya,Szabo Aniko^ORCID,Schinke Carolina^ORCID,Dhakal Binod^ORCID,Lentzsch Suzanne,D’Souza Anita,Mohyuddin Ghulam Rehman^ORCID,Julian Kelley,Midha Shonali,Costello Patrick,Kaiser Martin^ORCID,Hing Melissa Ng Liet,Harrison Simon J.^ORCID,Cliff Edward R. Scheffer^ORCID,Mohan Meera

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-01114-7.pdf

Reference19 articles.

1. Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel J, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495–505.

2. Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Prince HM, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259–67.

3. D’Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen × CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2022;40:3576–86.

4. Jagannath S, Richter J, Dhodapkar MV, Hoffman JE, Lee HC, Suvannasankha A, et al. Patterns of response to 200 Mg linvoseltamab in patients with relapsed/refractory multiple myeloma: longer follow-up of the linker-MM1 study. Blood. 2023;1424746.

5. Bar N, Mateos MV, Ribas P, Hansson M, Paris L, Hofmeister CC, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-cell maturation antigen (BCMA) × CD3 T-cell engager (TCE), administered subcutaneously (SC) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): updated results from a phase 1 first-in-human clinical study. Blood. 2023;142:2011.